Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

European Society for Medical Oncology 2020

European Society for Medical Oncology 2020 editorial memo (2021) 14:130–131 https://doi.org/10.1007/s12254-021-00712-6 Rupert Bartsch Accepted: 13 April 2021 © Springer-Verlag GmbH Austria, part of Springer Nature 2021 The 2020 Congress of the European Society for Medi- sisting of durvalumab and tremelimumab to first-line cal Oncology (ESMO) was another large meeting held chemotherapy, again indicating the relative treatment solely in a virtual format due to the ongoing severe resistance of pancreatic cancer. acute respiratory syndrome coronavirus 2 (SARS-CoV- Treatment of NSCLC was revolutionized in recent 2) pandemic. While we all have—to a certain ex- years and Dr. Kiesewetter summarizes the most re- tent—become used to the transfer of large parts of cent developments [3]. At the 2020 ESMO congress, our professional lives into the virtual world, following the focus was not on immunotherapy but on tyrosine developments outside our own field of expertise has kinase inhibitors (TKIs) with the ADAURA trial being become more difficult. Therefore, reviews focusing on a shining example: Adjuvant therapy with osimertinib congress highlights have gained importance and in was already shown to improve DFS over placebo in re- the current issue, the Magazine of European Medical sected NSCLC harbouring activating EGFR mutations. Oncology (MEMO) provides a series of articles focus- Central nervous http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

European Society for Medical Oncology 2020

Loading next page...
 
/lp/springer-journals/european-society-for-medical-oncology-2020-nq05QxQUgP
Publisher
Springer Journals
Copyright
2021 Springer-Verlag GmbH Austria, part of Springer Nature
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-021-00712-6
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2021) 14:130–131 https://doi.org/10.1007/s12254-021-00712-6 Rupert Bartsch Accepted: 13 April 2021 © Springer-Verlag GmbH Austria, part of Springer Nature 2021 The 2020 Congress of the European Society for Medi- sisting of durvalumab and tremelimumab to first-line cal Oncology (ESMO) was another large meeting held chemotherapy, again indicating the relative treatment solely in a virtual format due to the ongoing severe resistance of pancreatic cancer. acute respiratory syndrome coronavirus 2 (SARS-CoV- Treatment of NSCLC was revolutionized in recent 2) pandemic. While we all have—to a certain ex- years and Dr. Kiesewetter summarizes the most re- tent—become used to the transfer of large parts of cent developments [3]. At the 2020 ESMO congress, our professional lives into the virtual world, following the focus was not on immunotherapy but on tyrosine developments outside our own field of expertise has kinase inhibitors (TKIs) with the ADAURA trial being become more difficult. Therefore, reviews focusing on a shining example: Adjuvant therapy with osimertinib congress highlights have gained importance and in was already shown to improve DFS over placebo in re- the current issue, the Magazine of European Medical sected NSCLC harbouring activating EGFR mutations. Oncology (MEMO) provides a series of articles focus- Central nervous

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jun 1, 2021

Keywords: oncology; medicine/public health, general

References